LIAN

LianBio [LIAN] Stock Forecast

Q: What is LianBio stock symbol ?

LianBio is a US stock, located in Princeton of Nj and trading under the symbol LIAN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LIAN Stock Summary

LIAN has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated Stocks

LIAN

In the News

LIAN Financial details

Company Rating

Neutral

Market Cap

34.47M

Income

-87.98M

Revenue

Book val./share

1.89

Cash/share

2.35

Dividend

Dividend %

Employees

163

Optionable

Shortable

Yes

Earnings

25 Mar 2024

P/E

-5.07

Forward P/E

PEG

0.59

P/S

P/B

2.21

P/C

0.14

P/FCF

-5.31

Quick Ratio

9.91

Current Ratio

10.06

Debt / Equity

0.01

LT Debt / Equity

EPS (TTM)

-0.81

EPS next Y

EPS next Q

EPS this Y

-82.14%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

10%

SMA20

SMA50

SMA100

Inst Own

74.32%

Inst Trans

-0.69%

ROA

-33%

ROE

-38%

ROC

-0.45%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.241-4.99

52W High

52W Low

RSI

Rel Volume

2.58

Avg Volume

959.84K

Volume

2.48M

Perf Week

2.7%

Perf Month

-93.54%

Perf Quarter

-90.78%

Perf Half Y

-77.21%

Beta

0.232

Volatility

0.01%, 1.85%

Prev Close

6.69%

Price

0.319

Change

6.3%

LIAN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0
Net income per share	-0.23	-1.33	-5.71	-1.02
Operating cash flow per share	-0.11	-0.93	-4.77	-0.92
Free cash flow per share	-0.11	-0.94	-4.79	-0.94
Cash per share	0.4	2.42	11.14	2.8
Book value per share	-0.15	-1.26	10.28	2.41
Tangible book value per share	-0.14	-0.93	11.26	2.72
Share holders equity per share	-0.15	-1.26	10.28	2.41
Interest debt per share	0	0.02	0.15	-0.1
Market cap	1.48B	1.44B	211.87M	176.99M
Enterprise value	1.44B	1.19B	-11.48M	102.11M
P/E ratio	-60.88	-10.33	-1.08	-1.6
Price to sales ratio	0	0	0	0
POCF ratio	-126.6	-14.69	-1.29	-1.78
PFCF ratio	-126.6	-14.56	-1.28	-1.75
P/B Ratio	-93.82	-10.86	0.6	0.68
PTB ratio	-93.82	-10.86	0.6	0.68
EV to sales	0	0	0	0
Enterprise value over EBITDA	-59.11	-8.83	0.06	-0.81
EV to operating cash flow	-122.95	-12.12	0.07	-1.03
EV to free cash flow	-122.95	-12.01	0.07	-1.01
Earnings yield	-0.02	-0.1	-0.93	-0.62
Free cash flow yield	-0.01	-0.07	-0.78	-0.57
Debt to equity	-0.03	-0.01	0.01	0.02
Debt to assets	0.01	0.01	0.01	0.01
Net debt to EBITDA	1.75	1.87	1.14	0.6
Current ratio	12.96	44.45	26.48	13.24
Interest coverage	0	0	-804.81	8.51
Income quality	0.48	0.7	0.84	0.9
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0
Research and developement to revenue	0	0	0	0
Intangibles to total assets	0	0	0	0
Capex to operating cash flow	0	0.01	0.01	0.02
Capex to revenue	0	0	0	0
Capex to depreciation	0	-11.66	-1.8	-1.83
Stock based compensation to revenue	0	0	0	0
Graham number	0.86	6.14	36.33	7.44
ROIC	1.65	1.04	-0.54	-0.47
Return on tangible assets	-0.56	-0.5	-0.46	-0.34
Graham Net	-0.14	-1.02	10.05	2.57
Working capital	40M	270.52M	384.56M	289.16M
Tangible asset value	-14.82M	-98.07M	387.34M	293.65M
Net current asset value	-15.35M	-100.61M	360.64M	286.46M
Invested capital	-0.03	-0.01	0.01	0.02
Average receivables	0	10.13M	13.15M	3.91M
Average payables	0	2.16M	3.78M	2.34M
Average inventory	0	485K	-2.54M	-3.02M
Days sales outstanding	0	0	0	0
Days payables outstanding	0	20.76K	2.24K	527.81
Days of inventory on hand	0	4.65K	-4.2K	0
Receivables turnover	0	0	0	0
Payables turnover	0	0.02	0.16	0.69
Inventory turnover	0	0.08	-0.09	0
ROE	1.54	1.05	-0.56	-0.42
Capex per share	0	-0.01	-0.03	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.2	-0.17	-0.22	-0.2	-0.22
Operating cash flow per share	-0.15	-0.28	-0.16	-0.18	-0.15
Free cash flow per share	-0.16	-0.29	-0.16	-0.18	-0.15
Cash per share	2.88	2.8	2.67	2.49	2.35
Book value per share	2.52	2.4	2.25	2.07	1.89
Tangible book value per share	2.83	2.72	2.56	2.38	2.2
Share holders equity per share	2.52	2.4	2.25	2.07	1.89
Interest debt per share	0.06	-0.07	0.01	0.03	0.03
Market cap	216.71M	177.33M	210.04M	244.33M	159.68M
Enterprise value	142.61M	102.45M	111.62M	143.58M	59.07M
P/E ratio	-2.47	-2.43	-2.18	-2.83	-1.66
Price to sales ratio	0	0	0	0	0
POCF ratio	-13.57	-5.77	-11.91	-12.65	-10.07
PFCF ratio	-12.82	-5.73	-11.9	-12.62	-9.97
P/B Ratio	0.79	0.68	0.87	1.1	0.79
PTB ratio	0.79	0.68	0.87	1.1	0.79
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-5.88	-3.5	-4.35	-5.73	-2.27
EV to operating cash flow	-8.93	-3.34	-6.33	-7.43	-3.72
EV to free cash flow	-8.44	-3.31	-6.32	-7.41	-3.69
Earnings yield	-0.1	-0.1	-0.11	-0.09	-0.15
Free cash flow yield	-0.08	-0.17	-0.08	-0.08	-0.1
Debt to equity	0.02	0.02	0.02	0.01	0.01
Debt to assets	0.01	0.01	0.01	0.01	0.01
Net debt to EBITDA	3.05	2.56	3.84	4.02	3.87
Current ratio	14.72	13.24	11.42	12.62	10.06
Interest coverage	-17.47	2.42	10.99	0	0
Income quality	0.73	1.68	0.73	0.89	0.66
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.06	0.01	0	0	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-3.35	-0.74	-0.06	-0.15	-0.49
Stock based compensation to revenue	0	0	0	0	0
Graham number	3.38	3.02	3.37	3.06	3.09
ROIC	-0.09	-0.11	-0.11	-0.11	-0.13
Return on tangible assets	-0.06	-0.06	-0.08	-0.08	-0.09
Graham Net	2.53	2.57	2.42	2.28	2.11
Working capital	302.21M	289.16M	270.13M	251.46M	232.18M
Tangible asset value	306.6M	293.65M	274.43M	255.51M	236.11M
Net current asset value	278.99M	286.46M	267.89M	249.81M	231.02M
Invested capital	0.02	0.02	0.02	0.01	0.01
Average receivables	9.18M	5.63M	2.86M	2.49M	1.42M
Average payables	1.63M	1.74M	3.44M	3.67M	4.07M
Average inventory	0	0	-1.98M	-1.98M	-905.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	610.24	413.21	1.51K	578.61	1.87K
Days of inventory on hand	0	0	-1.1K	0	-543.27
Receivables turnover	0	0	0	0	0
Payables turnover	0.15	0.22	0.06	0.16	0.05
Inventory turnover	0	0	-0.08	0	-0.17
ROE	-0.08	-0.07	-0.1	-0.1	-0.12
Capex per share	-0.01	0	0	0	0

LIAN Frequently Asked Questions

What is LianBio stock symbol ?

LianBio is a US stock , located in Princeton of Nj and trading under the symbol LIAN

What is LianBio stock quote today ?

LianBio stock price is $0.319 today.

Is LianBio stock public?

Yes, LianBio is a publicly traded company.

Something similar

Top by Market Cap

NVD.DE

Company Profile

Volume Average 959.84K
Market Capitalization 34.47M
Employee 163
CEO Mr. Adam Leo Stone
Headquarters Princeton,NJ,US
IPO Date 2021-11-01
Website https://www.lianbio.com

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.